These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 32299813)

  • 41. Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties.
    Biasco G; Derenzini E; Grazi G; Ercolani G; Ravaioli M; Pantaleo MA; Brandi G
    Cancer Treat Rev; 2006 May; 32(3):214-28. PubMed ID: 16546323
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases.
    Feng QY; Wei Y; Chen JW; Chang WJ; Ye LC; Zhu DX; Xu JM
    World J Gastroenterol; 2014 Apr; 20(15):4263-75. PubMed ID: 24764664
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clonal Evolution of MEK/MAPK Pathway Activating Mutations in a Metastatic Colorectal Cancer Case.
    Lehtomaki KI; Lahtinen LI; Rintanen N; Kuopio T; Kholova I; Makela R; Rantala JK; Kellokumpu-Lehtinen PL; Kononen J
    Anticancer Res; 2019 Nov; 39(11):5867-5877. PubMed ID: 31704811
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness of prehepatectomy intra-arterial chemotherapy for multiple bilobar colorectal cancer metastases to the liver: a clinicopathologic study of peritumoral vasculobiliary invasion.
    Tanaka K; Shimada H; Kubota K; Ueda M; Endo I; Sekido H; Togo S
    Surgery; 2005 Feb; 137(2):156-64. PubMed ID: 15674195
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy.
    Tamandl D; Klinger M; Eipeldauer S; Herberger B; Kaczirek K; Gruenberger B; Gruenberger T
    Ann Surg Oncol; 2011 Feb; 18(2):421-30. PubMed ID: 20844968
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [HEMIHEPATECTOMY FOR RESECTABLE HEPATIC METASTASIS FROM COLORECTAL CANCER WITH POOR PROGNOSIS].
    Patyutko YI; Kotelnikov AG; Mamontov KG; Podluzhny DV; Ponomarenko AA
    Vopr Onkol; 2015; 61(3):439-47. PubMed ID: 26242159
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.
    Vlachogiannis G; Hedayat S; Vatsiou A; Jamin Y; Fernández-Mateos J; Khan K; Lampis A; Eason K; Huntingford I; Burke R; Rata M; Koh DM; Tunariu N; Collins D; Hulkki-Wilson S; Ragulan C; Spiteri I; Moorcraft SY; Chau I; Rao S; Watkins D; Fotiadis N; Bali M; Darvish-Damavandi M; Lote H; Eltahir Z; Smyth EC; Begum R; Clarke PA; Hahne JC; Dowsett M; de Bono J; Workman P; Sadanandam A; Fassan M; Sansom OJ; Eccles S; Starling N; Braconi C; Sottoriva A; Robinson SP; Cunningham D; Valeri N
    Science; 2018 Feb; 359(6378):920-926. PubMed ID: 29472484
    [TBL] [Abstract][Full Text] [Related]  

  • 48. RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases.
    Zimmitti G; Shindoh J; Mise Y; Kopetz S; Loyer EM; Andreou A; Cooper AB; Kaur H; Aloia TA; Maru DM; Vauthey JN
    Ann Surg Oncol; 2015 Mar; 22(3):834-842. PubMed ID: 25227306
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases.
    Jin K; Lan H; Cao F; Han N; Xu Z; Li G; He K; Teng L
    Int J Oncol; 2012 Aug; 41(2):583-8. PubMed ID: 22581265
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses.
    de Witte CJ; Espejo Valle-Inclan J; Hami N; Lõhmussaar K; Kopper O; Vreuls CPH; Jonges GN; van Diest P; Nguyen L; Clevers H; Kloosterman WP; Cuppen E; Snippert HJG; Zweemer RP; Witteveen PO; Stelloo E
    Cell Rep; 2020 Jun; 31(11):107762. PubMed ID: 32553164
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Choice of surgical strategy for colorectal liver metastases depending on clinical and pathological response to neoadjuvant chemo- and targeted therapy].
    Jakab F
    Orv Hetil; 2010 Nov; 151(47):1956-60. PubMed ID: 21071308
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Platform combining statistical modeling and patient-derived organoids to facilitate personalized treatment of colorectal carcinoma.
    Ramzy GM; Norkin M; Koessler T; Voirol L; Tihy M; Hany D; McKee T; Ris F; Buchs N; Docquier M; Toso C; Rubbia-Brandt L; Bakalli G; Guerrier S; Huelsken J; Nowak-Sliwinska P
    J Exp Clin Cancer Res; 2023 Apr; 42(1):79. PubMed ID: 37013646
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bevacizumab improves survival in patients with synchronous colorectal liver metastases provided the primary tumor is resected first.
    Lim C; Doussot A; Osseis M; Esposito F; Salloum C; Calderaro J; Tournigand C; Azoulay D
    Clin Transl Oncol; 2018 Oct; 20(10):1274-1279. PubMed ID: 29594943
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Successful right hepatectomy after four treatments of yttrium-90 microspheres (SIR-Spheres) and concomitant FOLFOX as bridging therapy to resection of colorectal liver metastases.
    Chua TC; Bester L; Akther J; Morris DL
    Anticancer Res; 2010 Jul; 30(7):3005-7. PubMed ID: 20683046
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
    Løes IM; Immervoll H; Sorbye H; Angelsen JH; Horn A; Knappskog S; Lønning PE
    Int J Cancer; 2016 Aug; 139(3):647-56. PubMed ID: 26991344
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement.
    Schwarz RE; Berlin JD; Lenz HJ; Nordlinger B; Rubbia-Brandt L; Choti MA
    HPB (Oxford); 2013 Feb; 15(2):106-15. PubMed ID: 23297721
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin.
    Arena S; Corti G; Durinikova E; Montone M; Reilly NM; Russo M; Lorenzato A; Arcella P; Lazzari L; Rospo G; Pagani M; Cancelliere C; Negrino C; Isella C; Bartolini A; Cassingena A; Amatu A; Mauri G; Sartore-Bianchi A; Mittica G; Medico E; Marsoni S; Linnebacher M; Abrignani S; Siena S; Di Nicolantonio F; Bardelli A
    Clin Cancer Res; 2020 Mar; 26(6):1372-1384. PubMed ID: 31831554
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study.
    Bower M; Metzger T; Robbins K; Tomalty D; Válek V; Boudný J; Andrasina T; Tatum C; Martin RC
    HPB (Oxford); 2010 Feb; 12(1):31-6. PubMed ID: 20495642
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment strategies for colorectal carcinoma with synchronous liver metastases: Which way to go?
    Ihnát P; Vávra P; Zonča P
    World J Gastroenterol; 2015 Jun; 21(22):7014-21. PubMed ID: 26078580
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Liver resection rate following downsizing chemotherapy with cetuximab in metastatic colorectal cancer: UK retrospective observational study.
    Malik H; Khan AZ; Berry DP; Cameron IC; Pope I; Sherlock D; Helmy S; Byrne B; Thompson M; Pulfer A; Davidson B
    Eur J Surg Oncol; 2015 Apr; 41(4):499-505. PubMed ID: 25703078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.